Cargando…

Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients

Current treatments for clear cell renal cell cancer (ccRCC) are insufficient because two-thirds of patients with metastases progress within two years. Here we report the identification and characterization of a cancer stem cell (CSC) population in ccRCC. CSCs are quantitatively correlated with tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendler, Annika, Bauer, Daniel, Busch, Jonas, Jung, Klaus, Wulf-Goldenberg, Annika, Kunz, Severine, Song, Kun, Myszczyszyn, Adam, Elezkurtaj, Sefer, Erguen, Bettina, Jung, Simone, Chen, Wei, Birchmeier, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026425/
https://www.ncbi.nlm.nih.gov/pubmed/32066735
http://dx.doi.org/10.1038/s41467-020-14700-7
Descripción
Sumario:Current treatments for clear cell renal cell cancer (ccRCC) are insufficient because two-thirds of patients with metastases progress within two years. Here we report the identification and characterization of a cancer stem cell (CSC) population in ccRCC. CSCs are quantitatively correlated with tumor aggressiveness and metastasis. Transcriptional profiling and single cell sequencing reveal that these CSCs exhibit an activation of WNT and NOTCH signaling. A significant obstacle to the development of rational treatments has been the discrepancy between model systems and the in vivo situation of patients. To address this, we use CSCs to establish non-adherent sphere cultures, 3D tumor organoids, and xenografts. Treatment with WNT and NOTCH inhibitors blocks the proliferation and self-renewal of CSCs in sphere cultures and organoids, and impairs tumor growth in patient-derived xenografts in mice. These findings suggest that our approach is a promising route towards the development of personalized treatments for individual patients.